Nebivolol deteriorates portal hemodynamics in cirrhotic rats by increasing splanchnic blood flow
T Reiberger, BA Payer, B Angermayr, V Fuhrmann, P Schwabl, B Jäger, T Hummel, T Horvatits, M Mitterhauser, M Peck-Radosavljevic · Zeitschrift für Gastroenterologie · 2011 · Heft 05
Bibliografische Angaben
Zusammenfassung
Introduction: Portal hypertension (P), as a function of Ohm's law (P=RxI) is influenced by intrahepatic resistance (R) and splanchnic blood flow (I). Non-selective beta-blockers (NSBB) decrease splanchnic blood flow and NO-donors (e.g. ISMN) decrease intrahepatic resistance, thus both drugs are used for treatment of portal hypertension. We evaluated the effects of Nebivolol, a third generation beta-blocker capable of increasing NO bioavailability on splanchnic and pulmonary hemodynamics in a cirrhotic rat model developing hepato-pulmonary syndrome (HPS). Methods: Male Sprague Dawley rats underwent bile duct liga…
